CSL Expands Into Cardio And Renal Disease Drugs Through $11.7 Billion Purchase of Vifor Pharma

Australian biotech firm CSL will purchase Swiss pharmaceutical company Vifor Pharma for $11.7 billion in a deal set to close in mid-2022, the companies announced.
Source: Drug Industry Daily